Shwachman-Diamond Syndrome Clinical Trial
— SDSROfficial title:
Shwachman Diamond Syndrome Registry and Study (SDS Registry)
NCT number | NCT06056908 |
Other study ID # | P00020466 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 19, 2016 |
Est. completion date | January 1, 2090 |
Shwachman-Diamond syndrome (SDS) is a genetic condition characterized by bone marrow failure, medical co-morbidities, and leukemia predisposition. SDS-Like patients share clinical features with SDS but lack mutations in known SDS genes. Since SDS/SDS-Like syndromes are rare diseases, data are sparse regarding the clinical features, natural history, clinical outcomes with current management, and treatment. For this reason, the SDS Registry was formed to collect clinical data from medical records and to bank biological samples with the goal of understanding SDS/SDS-Like diseases to develop better treatments and improve the health of patients with these conditions.
Status | Recruiting |
Enrollment | 5000 |
Est. completion date | January 1, 2090 |
Est. primary completion date | January 1, 2090 |
Accepts healthy volunteers | |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: Shwachman Diamond syndrome, Shwachman-Diamond Syndrome-Like conditions, or a genetically undefined condition that shares clinical features with Shwachman Diamond Syndrome. - Biallelic mutations in SBDS, or pathogenic mutations in DNAJC21, EFL1, or SRP54 OR - Shwachman-Diamond Syndrome defined clinically OR - Clinically suspected Shwachman-Diamond Syndrome OR - Phenotypic features suggestive of SDS OR - Parents, siblings, and other blood relatives of any age, living and deceased, of patients with SDS or SDS-Like conditions are eligible for this study Exclusion Criteria: • Patients with other diagnosed causes of bone marrow failure, exocrine pancreatic insufficiency and cancer predisposition will be excluded. |
Country | Name | City | State |
---|---|---|---|
United States | Children's Hospital Colorado | Aurora | Colorado |
United States | Boston Children's Hospital | Boston | Massachusetts |
United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
United States | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio |
Lead Sponsor | Collaborator |
---|---|
Boston Children's Hospital | Children's Hospital Medical Center, Cincinnati |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Characterize the natural history, medical complications, and treatment outcomes for patients with SDS and SDS-Like conditions. | The SDSR will collect clinical information regarding SDS and SDS-Like conditions. The goal is to understand the natural history, treatment outcomes and complications of these rare disorders in order to improve diagnosis, medical management, and treatment. | 50 years | |
Primary | Investigate the molecular and genetic pathogenesis of SDS/SDS-Like condtions and their complications such as marrow failure and clonal evolution. | The SDSR will coordinate a repository of blood, cord blood, bone marrow, saliva, skin fibroblast, and tumor samples and cell lines from patients with SDS and SDS-Like conditions for basic science studies of molecular and genetic pathways causing these disorders and their complications. We will also study how genetic/molecular pathways may be targeted or corrected for the development of new therapies. To this end, we will create immortalized cell lines including EBV-transformed lymphoblasts, immortalized fibroblasts, and induced pluripotent stem cells. These cell lines will provide a renewable source of rare patient-derived material for these studies. | 50 years | |
Primary | Identify new genes causing SDS/SDS-Like conditions | The SDSR will sequence DNA from patient samples to try to identify new genes that are involved in SDS/SDS-like phenotypes. | 50 years | |
Primary | Provide education on the diagnosis, medical management, and treatment of SDS/SDS-Like conditions for patients, families, and the medical/scientific community. | The SDSR will disseminate information through the study website, conferences, and other scientific publications. | 50 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02179359 -
Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies
|
N/A | |
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Completed |
NCT00176852 -
Stem Cell Transplant for Hemoglobinopathy
|
Phase 2/Phase 3 | |
Completed |
NCT00176878 -
Stem Cell Transplant for Bone Marrow Failure Syndromes
|
Phase 2/Phase 3 | |
Completed |
NCT01917708 -
Bone Marrow Transplant With Abatacept for Non-Malignant Diseases
|
Phase 1 | |
Completed |
NCT00499070 -
Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment
|
N/A | |
Recruiting |
NCT04275479 -
Diabetes/ Endocrine Surveillance in SDS
|
||
Completed |
NCT01529827 -
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 | |
Active, not recruiting |
NCT03333486 -
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT04965597 -
Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)
|
Phase 2 |